The global radiation therapy in oncology market is entering a decisive growth phase as precision-driven cancer care becomes the new standard across healthcare systems. Valued at USD 8.7 billion in 2025 and projected to reach USD 9.7 billion in 2026, the market is expected to climb to nearly USD 20.3 billion by 2035, expanding at a CAGR of 8.5% during the forecast period.
This momentum is being driven by a sharp rise in global
cancer incidence and a parallel shift toward technology-enabled,
outcome-focused treatment models. Healthcare providers are no longer just
expanding capacity—they are upgrading capabilities. Advanced modalities such as
image-guided, intensity-modulated, and stereotactic radiation therapies are
transforming how tumors are targeted, improving precision while minimizing
damage to healthy tissue.
Radiation therapy is now firmly positioned as a core pillar
of modern oncology. Its ability to integrate seamlessly with surgery,
chemotherapy, and immunotherapy makes it indispensable in multidisciplinary
cancer treatment strategies. At the same time, continuous innovation in
treatment planning software, automation, and adaptive therapy is enhancing
efficiency and clinical outcomes, making it a preferred option across a wide
range of cancer types.
Government-led cancer control programs are further
accelerating adoption. Increasing investments in hospital infrastructure,
digital imaging, and specialized radiotherapy centers—particularly across
emerging economies—are expanding access to advanced cancer care. Data-driven
healthcare planning and strengthened cancer registries are also enabling more
effective deployment of radiotherapy resources globally.
No comments:
Post a Comment